However, because of the more restricted distribution of its receptors to the epithelial lining in particular of the respiratory tract, and a sustained long-term induction of ISGs, IFN-λ1 therapy can have a more important role in the prevention of viral infections with probable causation of fewer side effects. This evidence concerns the gene IFNL1 and viral infectious disease.